CSK [The Human Chemical-Genetic Interaction Map Project]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
======= CSK =======


== Gene Information ==
  * **<color #00a2e8>Official Symbol</color>**: CSK
  * **<color #00a2e8>Official Name</color>**: C-terminal Src kinase
  * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A
  * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=1445|1445]]
  * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/P41240|P41240]]
  * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=CSK&organism=9606|BioGRID]]
  * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20CSK|Open PubMed]]
  * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/124095|Open OMIM]]

== Function Summary ==
  * **<color #00a2e8>Entrez Summary</color>**: N/A
  * **<color #00a2e8>UniProt Summary</color>**:  Non-receptor tyrosine-protein kinase that plays an important role in the regulation of cell growth, differentiation, migration and immune response. Phosphorylates tyrosine residues located in the C-terminal tails of Src-family kinases (SFKs) including LCK, SRC, HCK, FYN, LYN or YES1. Upon tail phosphorylation, Src-family members engage in intramolecular interactions between the phosphotyrosine tail and the SH2 domain that result in an inactive conformation. To inhibit SFKs, CSK is recruited to the plasma membrane via binding to transmembrane proteins or adapter proteins located near the plasma membrane. Suppresses signaling by various surface receptors, including T- cell receptor (TCR) and B-cell receptor (BCR) by phosphorylating and maintaining inactive several positive effectors such as FYN or LCK. {ECO:0000269|PubMed:1639064, ECO:0000269|PubMed:9281320}.

<button type='primary' size='sm' modal='Pfam_Domains'>Pfam Domains</button>
<button type='primary' size='sm' modal='GO_terms'>GO Terms</button>


<modal id='Pfam_Domains' size='lg' title='Pfam Domains'>
|Pkinase|
|SH3 1|
|SH2|
|Pkinase Tyr|
|SH3 2|
</modal>

<modal id='GO_terms' size='lg' title='GO Terms'>
|negative regulation of Golgi to plasma membrane protein transport|
|negative regulation of low-density lipoprotein particle clearance|
|regulation of Golgi to plasma membrane protein transport|
|negative regulation of lipoprotein particle clearance|
|regulation of low-density lipoprotein particle clearance|
|regulation of Fc receptor mediated stimulatory signaling pathway|
|protein kinase A catalytic subunit binding|
|negative regulation of bone resorption|
|negative regulation of bone remodeling|
|regulation of lipoprotein particle clearance|
|proline-rich region binding|
|negative regulation of tissue remodeling|
|negative regulation of phagocytosis|
|negative regulation of protein localization to plasma membrane|
|negative regulation of protein localization to cell periphery|
|negative regulation of protein localization to membrane|
|regulation of bone resorption|
|negative regulation of interleukin-6 production|
|non-membrane spanning protein tyrosine kinase activity|
|regulation of bone remodeling|
|T cell costimulation|
|lymphocyte costimulation|
|negative regulation of ERK1 and ERK2 cascade|
|oligodendrocyte differentiation|
|regulation of tissue remodeling|
|adherens junction organization|
|protein phosphatase binding|
|protein tyrosine kinase activity|
|regulation of protein localization to plasma membrane|
|regulation of phagocytosis|
|negative regulation of cellular protein localization|
|regulation of protein localization to cell periphery|
|regulation of interleukin-6 production|
|peptidyl-tyrosine phosphorylation|
|peptidyl-tyrosine modification|
|negative regulation of MAPK cascade|
|glial cell differentiation|
|cell-cell junction|
|T cell receptor signaling pathway|
|negative regulation of protein transport|
|negative regulation of establishment of protein localization|
|regulation of protein localization to membrane|
|protein C-terminus binding|
|protein autophosphorylation|
|positive regulation of T cell activation|
|gliogenesis|
|cell junction organization|
|positive regulation of leukocyte cell-cell adhesion|
|membrane raft|
|negative regulation of kinase activity|
|positive regulation of cell-cell adhesion|
|positive regulation of MAP kinase activity|
|cellular response to peptide hormone stimulus|
|negative regulation of cytokine production|
|negative regulation of transferase activity|
|regulation of ERK1 and ERK2 cascade|
|antigen receptor-mediated signaling pathway|
|regulation of leukocyte cell-cell adhesion|
|regulation of T cell activation|
|cellular response to peptide|
|positive regulation of protein serine/threonine kinase activity|
|regulation of MAP kinase activity|
|positive regulation of lymphocyte activation|
|response to peptide hormone|
|regulation of cell-cell adhesion|
|positive regulation of cell adhesion|
|positive regulation of leukocyte activation|
|negative regulation of protein phosphorylation|
|positive regulation of cell activation|
|negative regulation of phosphorylation|
|immune response-activating cell surface receptor signaling pathway|
|response to peptide|
|immune response-regulating cell surface receptor signaling pathway|
|negative regulation of transport|
|negative regulation of intracellular signal transduction|
|regulation of lymphocyte activation|
|regulation of protein serine/threonine kinase activity|
|positive regulation of protein kinase activity|
|regulation of cellular protein localization|
|positive regulation of MAPK cascade|
|regulation of vesicle-mediated transport|
|negative regulation of phosphate metabolic process|
|negative regulation of phosphorus metabolic process|
|immune response-activating signal transduction|
|positive regulation of kinase activity|
|negative regulation of protein modification process|
|immune response-regulating signaling pathway|
|cellular response to organonitrogen compound|
|regulation of leukocyte activation|
|cellular response to hormone stimulus|
|adaptive immune response|
|activation of immune response|
|regulation of cell activation|
|positive regulation of transferase activity|
|cellular response to nitrogen compound|
|negative regulation of cell population proliferation|
|regulation of cell adhesion|
|regulation of cytokine production|
|regulation of protein transport|
|regulation of peptide transport|
|brain development|
|regulation of establishment of protein localization|
|regulation of MAPK cascade|
|head development|
|negative regulation of catalytic activity|
|regulation of protein kinase activity|
|positive regulation of immune response|
|regulation of kinase activity|
|peptidyl-amino acid modification|
|response to hormone|
|regulation of cellular localization|
|protein phosphorylation|
|regulation of transferase activity|
|central nervous system development|
|response to organonitrogen compound|
|positive regulation of protein phosphorylation|
|positive regulation of intracellular signal transduction|
|regulation of protein localization|
|negative regulation of cellular protein metabolic process|
|cellular response to oxygen-containing compound|
|positive regulation of phosphorylation|
|identical protein binding|
|response to nitrogen compound|
|negative regulation of protein metabolic process|
|positive regulation of phosphate metabolic process|
|positive regulation of phosphorus metabolic process|
|negative regulation of molecular function|
|regulation of immune response|
|positive regulation of immune system process|
|negative regulation of multicellular organismal process|
|cellular response to endogenous stimulus|
|positive regulation of protein modification process|
|negative regulation of signal transduction|
|phosphorylation|
|negative regulation of cell communication|
|negative regulation of signaling|
|positive regulation of catalytic activity|
|regulation of protein phosphorylation|
|response to endogenous stimulus|
|ATP binding|
|response to oxygen-containing compound|
|regulation of phosphorylation|
|positive regulation of cellular protein metabolic process|
|regulation of cell population proliferation|
|negative regulation of response to stimulus|
|neurogenesis|
|positive regulation of signal transduction|
|regulation of immune system process|
|positive regulation of protein metabolic process|
|positive regulation of molecular function|
|regulation of phosphate metabolic process|
|regulation of phosphorus metabolic process|
|positive regulation of cell communication|
|positive regulation of signaling|
|regulation of intracellular signal transduction|
|regulation of protein modification process|
|regulation of transport|
|immune response|
</modal>
\\

 === CRISPR Data ===
<button type='primary' size='small' modal='Compound_Hit'>Compound Hit</button>
<button type='primary' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button>
<button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button>

<modal id='Compound_Hit' size='lg' title='Compound Hit'>
^Screen^Score^
|[[:results:exp122|Golgicide-A 4μM R03 exp122]]|-3.21|
|[[:results:exp455|Benzoate 10000μM R08 exp455]]|-3.16|
|[[:results:exp502|Milciclib 2μM R08 exp502]]|-3.01|
|[[:results:exp102|Nifuroxazide 5μM R03 exp102]]|-2.99|
|[[:results:exp233|EPZ-5676 30μM R05 exp233]]|-2.98|
|[[:results:exp134|MS023 2μM R03 exp134]]|-2.7|
|[[:results:exp519|RS-1 10μM R08 exp519]]|-2.58|
|[[:results:exp234|Ethanol 0.01 R05 exp234]]|-2.54|
|[[:results:exp514|Phorbol-12-myristate-13-acetate 0.57μM R08 exp514]]|-2.54|
|[[:results:exp359|FK-506 30μM R07 exp359]]|-2.53|
|[[:results:exp274|Citral 50μM R06 exp274]]|-2.52|
|[[:results:exp480|ETC-159 50μM R08 exp480]]|-2.51|
|[[:results:exp242|Radicicol 0.16μM R05 exp242]]|-2.51|
|[[:results:exp468|CB-5083 0.4μM R08 exp468]]|-2.5|
|[[:results:exp520|Rucaparib 6.5μM R08 exp520]]|-2.48|
|[[:results:exp17|DABN 20μM R00 exp17]]|-2.4|
|[[:results:exp275|Citral 75μM R06 exp275]]|-2.33|
|[[:results:exp21|MLN-4924 0.2μM R00 exp21]]|-2.29|
|[[:results:exp526|Sulforaphane 9μM R08 exp526 no dilution day6]]|-2.29|
|[[:results:exp219|A-395N 10μM R05 exp219]]|-2.23|
|[[:results:exp453|B02 10μM R08 exp453]]|-2.23|
|[[:results:exp458|Bisphenol S 100μM R08 exp458]]|-2.22|
|[[:results:exp6|Bortezomib 0.005μM R00 exp6]]|-2.22|
|[[:results:exp443|SNS-032 15μM R08 exp443]]|-2.22|
|[[:results:exp442|Ibrutinib 10μM R08 exp442]]|-2.21|
|[[:results:exp216|Erlotinib 10μM R05 exp216]]|-2.2|
|[[:results:exp264|Arsenate 40μM R06 exp264]]|-2.19|
|[[:results:exp452|Azithromycin 100μM R08 exp452]]|-2.15|
|[[:results:exp534|Trientine 500μM R08 exp534]]|-2.12|
|[[:results:exp437|Ethanol 0.003 R08 exp437]]|-2.06|
|[[:results:exp214|2-Deoxy-D-glucose 800μM R05 exp214]]|-2.03|
|[[:results:exp190|Vincristine 0.0005μM R04 exp190]]|-2.03|
|[[:results:exp535|Trimetrexate 0.03μM R08 exp535]]|-2.02|
|[[:results:exp432|YM155 0.001μM R08 exp432]]|-2|
|[[:results:exp48|Mubritinib 0.2μM R01 exp48]]|-1.97|
|[[:results:exp148|SB202190 10μM R03 exp148]]|-1.96|
|[[:results:exp30|Rapamycin 10μM R00 exp30]]|-1.95|
|[[:results:exp334|All-trans-Retinoic-Acid 40μM R07 exp334]]|-1.94|
|[[:results:exp357|Dorsomorphin 5μM R07 exp357]]|-1.94|
|[[:results:exp488|Hippuristanol 0.12μM R08 exp488]]|-1.94|
|[[:results:exp489|Hippuristanol 0.12μM R08 exp489 no dilution day6]]|-1.93|
|[[:results:exp263|Aphidicolin 0.04μM R06 exp263]]|-1.88|
|[[:results:exp362|GSK-J4 1μM R07 exp362]]|-1.8|
|[[:results:exp241|QNZ 0.01μM R05 exp241]]|-1.79|
|[[:results:exp288|HMS-I2 10μM R06 exp288]]|-1.78|
|[[:results:exp246|UM0011500 10μM R05 exp246]]|-1.78|
|[[:results:exp429|Rapamycin 0.001μM R08 exp429]]|-1.77|
|[[:results:exp438|NN-Diethyl-meta-toluamide 500μM R08 exp438]]|-1.76|
|[[:results:exp218|A-395 10μM R05 exp218]]|-1.74|
|[[:results:exp444|THZ531 0.225μM R08 exp444]]|-1.74|
|[[:results:exp317|Geldanamycin 0.015 to 0.05μM on day4 R07 exp317]]|-1.73|
|[[:results:exp45|Docetaxel 0.002μM R01 exp45]]|-1.7|
|[[:results:exp410|THZ531 0.11 to 0.125μM on day4 R07 exp410]]|-1.7|
|[[:results:exp66|BI-D1870 3.15μM R02 exp66]]|1.72|
|[[:results:exp36|TRAIL 50ng/ml R00 exp36]]|1.82|
</modal>

<modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'>
^Gene^Correlation^
|[[:human genes:p:pag1|PAG1]]|0.575|
|[[:human genes:p:pten|PTEN]]|0.572|
|[[:human genes:i:irf4|IRF4]]|0.475|
|[[:human genes:h:hars|HARS]]|0.428|
|[[:human genes:a:abcf3|ABCF3]]|0.425|
|[[:human genes:p:pde7a|PDE7A]]|0.405|
|[[:human genes:f:foxo1|FOXO1]]|0.4|
</modal>

<modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'>
Global Fraction of Cell Lines Where Essential: 1/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
</modal>

== Essentiality in NALM6  ==
    * **<color #00a2e8>Essentiality Rank</color>**: 4496
    * **<color #00a2e8>Expression level (log2 read counts)</color>**: 7.51 
<button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button>
<modal id='Dist_expr' size='lg' title='CSK Expression in NALM6 Cells: 7.51'>
{{:chemogenomics:nalm6 dist.png?nolink |}}
</modal>